Abstract
Clostridium difficile infection (CDI) is an increasing problem in hospitalized patients. Recurrences of disease, despite the recommended treatments with metronidazole or vancomycin, are frequently seen and pose major problems for the clinical management of patients with CDI. Evidence for efficient clinical cure and low recurrence rates with primary use of alternative antibacterial treatment, such as fidaxomicin and rifaximin, is growing andthese treatment strategies need further exploration. The use of probiotics (e.g. Saccharomyces boulardii) may be considered, as well as combination therapy with vancomycin. Other promising therapies are the use of (monoclonal) antibodies and faecal transplantation, the efficacy of which has been suggested in smaller studies. Large studies evaluating faecal transplantation and other microbial products are underway. This article focuses on recurrent CDI and the possibilities for treatment and reduction of recurrence rates. Furthermore, general concepts of CDI and the primary treatment strategies are discussed. In summary, recurrent CDI remains a challenging clinical entity for which more treatment options will be forthcoming in the next few years.
Similar content being viewed by others
References
Pépin J, Routhier S, Gagnon S, et al. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006 Mar; 42(6): 758–64
Bauer M, Notermans D, van Benthem B, et al., ECDIS Study Group. Clostridium difficile infection in Europe: a hospital-based survey. Lancet 2011 Jan; 377(9759): 63–73
Bouza E, Munoz P, Alonso R. Clinical manifestations, treatment and control of infections caused by Clostridium difficile. Clin Microbiol Infect 2005 Jul; 11 Suppl. 4: 57–64
Fekety R. Guidelines for the diagnosis and management of Clostridium difficile-associated diarrhea and colitis. American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol 1997 May; 92(5): 739–50
Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007 Jul; (3): CD004610
Bartlett J. Clinical practice: antibiotic-associated diarrhea. N Engl J Med 2002 Jan; 346(5): 334–9
Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2005 Jan; (1): CD004610
Hu M, Katchar K, Kyne L, et al. Prospective derivation and validation of a clinical prediction rule for recurrent Clostridium difficile infection. Gastroenterology 2009 Apr; 136(4): 1206–14
Kyne L, Farrell R, Kelly C. Clostridium difficile. Gastroenterol Clin North Am 2001 Sep; 30(3): 753–77
Kyne L, Warny M, Qamar A, et al. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhoea. Lancet 2001 Jan; 357(9251): 189–93
Moyenuddin M, Williamson J, Ohl C. Clostridium difficile-associated diarrhea: current strategies for diagnosis and therapy. Curr Gastroenterol Rep 2002 Aug; 4(4): 279–86
Musher DM, Logan N, Hamill R, et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006 Aug; 43(4): 421–7
Pepin J, Alary M, Valiquette L, et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005 Jun; 40(11): 1591–7
McFarland L, Elmer G, Surawicz C. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002 Jul; 97(7): 1769–75
Best E, Fawley W, Parnell P, et al. The potential for airborne dispersal of Clostridium difficile from symptomatic patients. Clin Infect Dis 2010 Jun; 50(11): 1450–7
Roberts K, Smith C, Snelling A, et al. Aerial dissemination of Clostridium difficile spores. BMC Infect Dis 2008 Jan; 24(8): 7–12
Donskey C. The role of the intestinal tract as a reservoir and source for transmission of nosocomial pathogens. Clin Infect Dis 2004 Jul; 15(39): 219–26
Kyne L, Warny M, Qamar A, et al. Asymptomatic carriage of Clostridium difficile and serum levels of IgG antibody against toxin A. N Engl J Med 2000 Feb; 342(6): 390–7
McFarland L, Mulligan M, Kwok R, et al. Nosocomial acquisition of Clostridium difficile infection. N Engl J Med 1989 Jan; 320(4): 204–10
Shim J, Johnson S, Samore M, et al. Primary symptomless colonisation by Clostridium difficile and decreased risk of subsequent diarrhoea. Lancet 1998 Feb; 351(9103): 633–6
Bakken J. Fecal bacteriotherapy for recurrent Clostridium difficile infection. Anaerobe 2009 Dec; 15(6): 285–9
Hopkins M, MacFarlane G. Changes in predominant bacterial populations in human faeces with age and with Clostridium difficile infection. J Med Microbiol 2002 May; 51(5): 448–54
McFarland L, Surawicz C, Rubin M, et al. Recurrent Clostridium difficile disease: epidemiology and clinical characteristics. Infect Control Hosp Epidemiol 1999 Jan; 20(1): 43–50
Fekety R, MacFarland L, Surawicz C, et al. Recurrent Clostridium difficile diarrhea: characteristics of and risk factors for patients enrolled in a prospective, randomized, double-blinded trial. Clin Infect Dis 1997 Mar; 24(3): 324–33
Loo V, Poirier L, Miller M, et al. A predominantly clonal multi-institutional outbreak of Clostridium difficile-associated diarrhea with high morbidity and mortality. N Engl J Med 2005 Dec; 353(23): 2442–9
White H, Wiselka M. Inpatient mortality and death reporting associated with Clostridium difficile infection in a large teaching hospital. J Hosp Infect. Epub 2011 Feb 11
Pépin J, Valiquette L, Gagnon S, et al. Outcomes of Clostridium difficile-associated disease treated with metronidazole or vancomycin before and after the emergence of NAP1/027. Am J Gastroenterol 2007 Dec; 102(12): 2781–8
Zar F, Bakkanagari S, Moorthi K, et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007 Aug; 45(3): 302–7
Gerding D. Treatment of Clostridium difficile-associated diarrhea and colitis. Curr Top Microbiol Immunol 2000; 250: 127–39
Dubberke E, Reske K, Yan Y, et al. Clostridium difficile-associated disease in a setting of endemicity: identification of novel risk factors. Clin Infect Dis 2007 Jun; 45(12): 1543–9
Owens Jr R, Donksey C, Gaynes R, et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008 Jan; 46 Suppl. 1: S19–31
Thomas C, Stevenson M, Riley T. Antibiotics and hospital-acquired Clostridium difficile-associated diarrhoea: a systematic review. J Antimicrob Chemother 2003 Jun; 51(6): 1339–50
Bignardi G. Risk factors for Clostridium difficile infection. J Hosp Infect 1998 Sep; 40(1): 1–15
Cunningham R, Dale B, Undy B, et al. Proton pump inhibitors as a risk factor for Clostridium difficile diarrhoea. J Hosp Infect 2003 Jul; 54(3): 243–5
Howell M, Novack V, Grgurich P, et al. Iatrogenic gastric acid suppression and the risk of nosocomial Clostridium difficile infection. Arch Intern Med 2010 May; 170(9): 784–90
Jung K, Park J, Chon Y, et al. Risk factors for treatment failure and recurrence after metronidazole treatment for clostridium difficile-associated diarrhea. Gut Liver 2010 Sep; 4(3): 332–7
Musher D, Aslam S, Logan N, et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005 Jun; 40(11): 1586–90
Cadena J, Thompson G, Patterson J, et al. Clinical predictors and risk factors for relapsing Clostridium difficile infection. Am J Med Sci 2010 Apr; 339(4): 350–5
Garey K, Sethi S, Yadav Y, et al. Meta-analysis to assess risk factors for recurrent Clostridium difficile infection. J Hosp Infect 2008 Dec; 70(4): 298–304
Johnson S. Recurrent Clostridium difficile infection: causality and therapeutic approaches. Int J Antimicrob Agents 2009 Mar; 33 Suppl.: S33–6
McFarland L, Surawicz C, Greenberg R, et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994 Jun; 271(24): 1913–8
Leung D, Kelly C, Boguniewicz M, et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991 Apr; 118 (4 Pt 1): 633–7
Warny M, Vaerman J, Avesani V, et al. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994 Feb; 62(2): 384–9
Goorhuis A, Bakker D, Corver J, et al. Emergence of Clostridium difficile infection due to a new hypervirulent strain, polymerase chain reaction ribotype 078. Clin Infect Dis 2008 Nov; 47(9): 1162–70
Lamontagne F, Labbe A, Haeck O, et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007 Feb; 245(2): 267–72
Louie T. How should we respond to the highly toxogenic NAP1/ribotype 027 strain of Clostridium difficile? CMAJ 2005 Oct; 173(9): 1049–50
McDonald L. Clostridium difficile: responding to a new threat from an old enemy. Infect Control Hosp Epidemiol 2005 Aug; 26(8): 672–5
Matamouros S, England P, Dupuy B. Clostridium difficile toxin expression is inhibited by the novel regulator TcdC. Mol Microbiol 2007 Jun; 64(5): 1274–88
Goorhuis A, van Dissel J, Kuijper E. Novel risk factors for Clostridium difficile-associated disease in a setting of endemicity? Clin Infect Dis 2008 Dec; 47(3): 429–30
Norén T. Clostridium difficile and the disease it causes. Methods Mol Biol 2010; 646: 9–35
Hecht D, Galang M, Sambol S, et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007 Aug; 51(8): 2716–9
Bauer M, Kuiper E, van Dissel J, European Society of Clinical Microbiology and Infectious Diseases. European Society of Clinical Microbiology and Infectious Diseases (ESCMID): treatment guidance document for Clostridium difficile infection (CDAD). Clin Microbiol Infect 2009 Dec; 15(12): 1067–79
Cohen S, Gerding D, Johnson S, et al., Society for Healthcare Epidemiology of America; Infectious Diseases Society of America. Clinical practice guidelines for Clostridium difficile infection in adults: 2010 update by the society for healthcare epidemiology of America (SHEA) and the infectious diseases society of America (IDSA). Infect Control Hosp Epidemiol 2010 May; 31(5): 431–55
Shah D, Dang M, Hasbun R, et al. Clostridium difficile infection: update on emerging antibiotic treatment options and antibiotic resistance. Expert Rev Anti Infect Ther 2010 May; 8(5): 555–64
Apisarnthanarak A, Razavi B, Mundy L. Adjunctive intracolonic vancomycin for severe Clostridium difficile colitis: case series and review of the literature. Clin Infect Dis 2002 Sep; 35(6): 690–6
Louie T, Gerson M, Grimard D, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [abstract no. K-4259]. In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2007 Sep 17–20; Washington (DC). Herndon (VA): American Society for Microbiology, 2007
Al-Nassir W, Sethi A, Nerandzic M, et al. Comparison of clinical and microbiological response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008 Jul; 47(1): 56–62
Johnson S, Sanchez J, Gerding D. Metronidazole resistance in Clostridium difficile. Clin Infect Dis 2000 Aug; 31(2): 625–6
Peláez T, Alcala L, Alonso R, et al. In vitro activity of ramoplanin against Clostridium difficile, including strains with reduced susceptibility to vancomycin or with resistance to metronidazole. Antimicrob Agents Chemother 2005 Mar; 49(3): 1157–9
Baines S, O'Connor R, Freeman J, et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008 Nov; 62(5): 1046–52
Bolton R, Culshaw M. Faecal metronidazole concentrations during oral and intravenous therapy for antibiotic associated colitis due to Clostridium difficile. Gut 1986 Oct; 27(10): 1169–72
Friedenberg F, Fernandez A, Kaul V, et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001 Aug; 44(8): 1176–80
Bartlett J. The case for vancomycin as the preferred drug for treatment of Clostridium difficile infection. Clin Infect Dis 2008 May; 46(10): 1489–92
Gonzales M, Pepin J, Frost E, et al. Faecal pharmaco-kinetics of orally administered vancomycin in patients with suspected Clostridium difficile infection. BMC Infect Dis 2010 Dec; 10(363): 1–7
Kuipers E, Surawicz C. Clostridium difficile infection. Lancet 2008 May; 371(9623): 1486–8
Koo H, Garey K, Dupont H. Future novel therapeutic agents for Clostridium difficile infection. Expert Opin Investig Drugs 2010 Jul; 19(7): 825–36
de Lalla F, Nicolin R, Rinaldi E, et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992 Oct; 36(10): 2192–6
Wenisch C, Parschalk B, Hasenhündl M, et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996 May; 22(5): 813–8
Koo H, DuPont H. Rifaximin: a unique gastrointestinal-selective antibiotic for enteric diseases. Curr Opin Gas-troenterol 2010 Jan; 26(1): 17–25
O'Connor J, Galang M, Sambol S, et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008 Aug; 52(8): 2813–7
Curry S, Marsh J, Shutt K, et al. High frequency of rifampin resistance identified in an epidemic Clostridium difficile clone from a large teaching hospital. Clin Infect Dis 2009 Feb; 15(48): 425–9
Neff G, Zacharias V, Kaiser T, et al. Rifaximin for the treatment of recurrent Clostridium difficile infection after liver transplantation: a case series. Liver Transpl 2010 Aug; 16(8): 960–3
Garey K, Jiang Z, Bellard A, et al. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea: an uncontrolled pilot study. J Clin Gastroenterol 2009 Jan; 43(1): 91–3
Johnson S, Schriever C, Galang M, et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007 Mar; 44(6): 846–8
Johnson S, Schriever C, Patel U, et al. Rifaximin redux: treatment of recurrent Clostridium difficile infections with rifaximin immediately post-vancomycin treatment. Anaerobe 2009 Dec; 15(6): 290–1
Drekonja D. Rifampin plus metronidazole for Clostridium difficile infection [letter]. Infect Control Hosp Epidemiol 2010 Nov; 31(11): 1205; author reply 1205-6
Lagrotteria D, Holmes S, Smieja M, et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006 Sep; 43(5): 547–52
Jiang Z, DuPont H, LaRocco M, et al. In vitro susceptibility of Clostridium difficile to rifaximin and rifampin in 359 consecutive isolates at a university hospitalin Houston, Texas. J Clin Pathol 2010 Apr; 63(4): 355–8
Herpers B, Vlaminckx B, Burkhardt O, et al. Intravenous tigecycline as adjunctive or alternative therapy for severe refractory Clostridium difficile infection. Clin Infect Dis 2009 Jun; 48(12): 1732–5
Lu C, Liu C, Liao C, et al. Severe and refractory Clostridium difficile infection successfully treated with tigecycline and metronidazole. Int J Antimicrob Agents 2010 Mar; 35(3): 311–2
Kopterides P, Papageorgiou C, Antoniadou A, et al. Failure of tigecycline to treat severe Clostridium difficile infection. Anaesth Intensive Care 2010 Jul; 38(4): 755–8
US Food and Drug Administration. FDA Drug Safety Communication: increased risk of death with tygacil (tigecycline) compared to other antibiotics used to treat similar infections [online]. Available from URL: http://www.fda.gov/Drugs/DrugSafety/ucm224370.htm [Accessed 2010 Dec 01]
Anderson V, Curran M. Nitazoxanide: a review of its use in the treatment of gastrointestinal infections. Drugs 2007; 67(13): 1947–67
Musher D, Logan N, Bressler A, et al. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009 Feb; 48(4): e41–6
Musher D, Logan N, Mehendiratta V, et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007 Apr; 59(4): 705–10
Dudley M, McLaughlin J, Carrington G, et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-induced diarrhea: a randomized double-blind trial. Arch Intern Med 1986 Jun; 146(6): 1101–4
Young G, Ward P, Bayley N, et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985 Nov; 89(5): 1038–45
Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004 Jul; 54(1): 211–6
Finegold S, Molitoris D, Vaisanen M, et al. In vitro activities of OPT-80 and comparator drugs against intestinal bacteria. Antimicrob Agents Chemother 2004 Dec; 48(12): 4898–902
Louie T, Miller M, Donskey C, et al. Clinical outcomes, safety, and pharmacokinetics of OPT-80 in a phase 2 trial with patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009 Jan; 53(1): 223–8
Miller M. Fidaxomicin (OPT-80) for the treatment of Clostridium difficile infection. Expert Opin Pharmacother 2010 Jun; 11(9): 1569–78
Miller M, Mullane K, Weiss K, et al. Faster time to resolution of diarrhea with fidaxomicin vs. vancomycin in patients with Clostridium difficile infection (CDAD) [poster no. 422]. 47th Annual Meeting of the Infectious Disease Society of America; 2009 Oct 29-Nov 1; Philadelphia (PA)
Louie T, Miller M, Mullane K, et al., the OPT-80-003 Clinical Study Group. Fidaxomicin versus vancomycin for Clostridium difficile infection. N Engl J Med 2011 Feb; 364(5): 422–31
Cornely O, Miller M, Louie T, et al. Randomized controlled trial (RCTt) of fidaxomicin (FDX) versus vancomycin (VAN) in treatment of recurrent Clostridium difficile infection (CDI) [abstract plus oral presentation]. 50th ICAAC; 2010 Sep 12–15; Boston (MA)
Weiss K. Toxin-binding treatment for Clostridium difficile: a review including reports of studies with tolevamer. Int J Antimicrob Agents 2009 Jan; 33(1): 4–7
Louie T, Gerson M, Grimard D, et al. Results of a phase III study comparing tolevamer, vancomycin and metronidazole in Clostridium difficile-associated diarrhea (CDAD) [poster no. K-425a]. 47th ICAAC; 2007 Sep 17–20; Chicago (IL)
Bouza E, Dryden M, Mohammed R, et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in the treatment of Clostridium difficile-associated diarrhoea [abstract no. O464]. 18th ECCMID; 2008 Apr 19–22; Barcelona
Kink JA, Williams JA. Antibodies to recombinant Clostridium difficile toxins A and B are an effective treatment and prevent relapse of C. difficile-associated disease in a hamster model of infection. Infect Immun 1998; 66(5): 2018–25
Lyerly DM, Bostwick EF, Binion SB, et al. Passive immunization of hamsters against disease caused by Clostridium difficile by use of bovine immunoglobulin G concentrate. Infect Immun 1991; 59(6): 2215–8
van Dissel JT, de Groot N, Hensgens CM, et al. Bovine antibody enriched whey to aid in the prevention of a relapse of Clostridium difficile-associated diarrhoea: pre-clinical and preliminary clinical data. J Med Microbiol 2005; 54 (Pt 2): 197–205
Gerding DN, Johnson S. Management of Clostridium difficile infection: thinking inside and outside the box. Clin Infect Dis 2010 Dec 1; 51(11): 1306–13
Numan S, Veldkamp P, Kuijper E, et al. Clostridium difficile-associated diarrhoea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007 Jun; 56(6): 888–9
Mattila E, Anttila V, Broas M, et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40(9): 702–8
Lowy I, Molrine D, Leav B, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010 Jan; 362(3): 197–205
Lee B, Popovich M, Tian Y, et al. The potential value of Clostridium difficile vaccine: an economic computer simulation model. Vaccine 2010 Jul; 28(32): 5245–53
Sougioultzis S, Kyne L, Drudy D, et al. Clostridium difficile toxoid vaccine in recurrent C. difficile-associated diarrhea. Gastroenterology 2005 Mar; 128(3): 764–70
O'Horo J, Safdar N. The role of immunoglobulin for the treatment of Clostridium difficile infection: a systematic review. Int J Infect Dis 2009 Nov; 13: 663–7
McPherson S, Rees C, Ellis R, et al. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006 May; 49(5): 640–5
Wilcox M. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004 May; 53(5): 882–4
Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008 Jan; (1): CD004611
Wilson K. The microecology of Clostridium difficile. Clin Infect Dis 1993 Jun; 16 Suppl. 4: S214–8
D'Souza A, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: meta-analysis. BMJ 2002; 324(7350): 1361
Lawrence S, Korzenik J, Mundy L. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005 Sep; 54 (Pt 9): 905–6
Surawicz C, MacFarland L, Greenberg R, et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000 Oct; 31(4): 1012–7
Wullt M, Hagslatt M, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35(6-7): 365–7
Lherm T, Monet C, Nougie`re B, et al. Seven cases of fungemia with Saccharomyces boulardii in critically ill patients. Intensive Care Med 2002 Jun; 28(6): 797–801
Muñoz P, Bouza E, Cuenca-Estrella M, et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005 Jun; 40(11): 1625–34
Garborg K, Waagsbo B, Stallemo A, et al. Results of faecal donor instillation therapy for recurrent Clostridium difficile-associated diarrhoea. Scand J Infect Dis 2010 Dec; 42(11-12): 857–61
Aas J, Gessert C, Bakken J. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003 Mar; 36(5): 580–5
Jorup-Rönström C, Hakanson A, Persson A, et al. Feces culture successful therapy in Clostridium difficile diarrhea [in Swedish]. Lakartidningen 2006 Nov; 103(46): 3603–5
Lund-Tønnesen S, Berstad A, Schreiner A, et al. Clostridium difficile-associated diarrhea treated with homologous feces [in Norwegian]. Tidsskr Nor Laegeforen 1998 Mar; 118(7): 1027–30
Nieuwdorp M, van Nood E, Speelman P, et al. Treatment of recurrent Clostridium difficile-associated diarrhoea with a suspension of donor faeces [in Dutch]. Ned Tijdschr Geneeskd 2008 Aug; 152(35): 1927–32
Persky S, Brandt L. Treatment of recurrent Clostridium difficile-associated diarrhea by administration of donated stool directly through a colonoscope. Am J Gastroenterol 2000 Nov; 95(11): 3283–5
Schwan A, Sjolin S, Trottestam U, et al. Relapsing Clostridium difficile enterocolitis cured by rectal infusion of normal faeces. Scand J Infect Dis 1984; 16(2): 211–5
Silverman M, Davis I, Pillai D. Success of self-administered home fecal transplantation for chronic Clostridium difficile infection. Clin Gastroenterol Hepatol 2010 May; 8(5): 471–3
Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989 May; 1(8648): 1156–60
Borody T, Warren E, Leis S, et al. Treatment of ulcerative colitis using fecal bacteriotherapy. J Clin Gastroenterol 2003 Jul; 37(1): 42–7
Academic Medical Center. The FECAL trial, Fecal therapy to eliminate clostridium difficile associated longstanding diarrhoea. [Nederlands Trial Register number 1171]. Nederlands Trial Register [online]. Available from URL: http://www.trialregister.nl/trialreg/admin/rctview.asp?TC=1177 [Accessed 2011 Apr 4]
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
van Nispen tot Pannerden, C.M.F., Verbon, A. & Kuipers, E.J. Recurrent Clostridium difficile Infection. Drugs 71, 853–868 (2011). https://doi.org/10.2165/11591230-000000000-00000
Published:
Issue Date:
DOI: https://doi.org/10.2165/11591230-000000000-00000